Your browser doesn't support javascript.
loading
Cost-effectiveness analysis on Imipenem-Cilastatin Sodium and Meropenem for severe infection / 中国综合临床
Clinical Medicine of China ; (12): 387-389, 2013.
Article in Chinese | WPRIM | ID: wpr-432058
ABSTRACT
Objective To evaluate the economic effects of Imipenem-Cilastatin Sodium and Meropenem for severe infection.Methods The therapeutic effects and costs of the two therapeutic schemes for severe infection were evaluated by using cost-minimization analysis.Results The total effective rates of Imipenemcilastatin group and Meropenem group in the treatment severe infection were 93.33% (28/30) and 85.71% (24/28),the difference were not statistically significant (x2 =4.89,P =0.082).The cost-effectiveness ratio (C/E) were 40.35 and 71.69 respectively.The cost of every unit increment of effectiveness for Meropenem group were 312.16 Yuan,more than that of the Imipenem-cilastatin group.Conclusion Cost-effectiveness ratio of Imipenem-cilastatin is superior to that of Meropenem,and Imipenem-cilastatin has obvious pharmacoeconomics advantage over Meropenem for severe infections.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Health economic evaluation Language: Chinese Journal: Clinical Medicine of China Year: 2013 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Health economic evaluation Language: Chinese Journal: Clinical Medicine of China Year: 2013 Type: Article